olmesartan medoxomil has been researched along with Atherogenesis in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaul, U; Mansoor, A; Sabbah, ZA | 1 |
| Chen, L; Li, H; Lu, YZ; Qi, GX; Shi, LY; Yu, B | 1 |
| Armstrong, ZB; Boughner, DR; Drangova, M; Rogers, KA | 1 |
| Mason, RP | 1 |
| Inaba, T; Kato, M; Kitayama, K; Koike, H; Mizuno, M; Sada, T | 1 |
| Chuma, H; Fukushima, Y; Kato, M; Koike, H; Mizuno, M; Sada, T; Terashima, H | 1 |
| Miyazaki, M; Takai, S | 1 |
2 review(s) available for olmesartan medoxomil and Atherogenesis
| Article | Year |
|---|---|
Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atherosclerosis; Humans; Hypertension; Imidazoles; Inflammation Mediators; Nitric Oxide; Olmesartan Medoxomil; Renin-Angiotensin System; Tetrazoles; Treatment Outcome | 2011 |
Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Atherosclerosis; C-Reactive Protein; Chemokine CCL2; Clinical Trials as Topic; Humans; Imidazoles; Interleukin-6; Olmesartan Medoxomil; Tetrazoles; Tumor Necrosis Factor-alpha | 2006 |
5 other study(ies) available for olmesartan medoxomil and Atherogenesis
| Article | Year |
|---|---|
Angiotensin receptor blockers - advantages of the new sartans.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Benzoates; Cardiovascular Diseases; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Oxadiazoles; Telmisartan; Tetrazoles; Treatment Outcome | 2013 |
[Impact of olmesartan medoxomil on atherosclerosis lesions in apolipoprotein E knockout mice].
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Cathepsins; Diet, High-Fat; Lipids; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Olmesartan Medoxomil; Plaque, Atherosclerotic | 2016 |
Angiotensin II type 1 receptor blocker inhibits arterial calcification in a pre-clinical model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Bone Morphogenetic Protein 2; Calcinosis; Diet, Atherogenic; Disease Models, Animal; Imidazoles; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Olmesartan Medoxomil; Osteoblasts; Osteocalcin; Phenotype; Rabbits; Receptor, Angiotensin, Type 1; Tetrazoles; Time Factors; X-Ray Microtomography | 2011 |
Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atherosclerosis; Blood Pressure; Chemokine CCL2; Cholesterol; Drug Therapy, Combination; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Imidazoles; Immunohistochemistry; Macrophages; Olmesartan Medoxomil; Pravastatin; Rabbits; Tetrazoles; Tunica Intima | 2005 |
Severity of hyperlipidemia does not affect antiatherosclerotic effect of an angiotensin II receptor antagonist in apolipoprotein E-deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Valve; Apolipoproteins E; Atherosclerosis; Blood Pressure; Cholesterol; Heart Rate; Hyperlipidemias; Imidazoles; Male; Mice; Mice, Inbred C57BL; Olmesartan Medoxomil; Tetrazoles; Triglycerides | 2006 |